TY  - JOUR
AU  - Gonzalez-Cao, Maria
AU  - Mayo de Las Casas, Clara
AU  - Oramas, Juana
AU  - Berciano-Guerrero, Miguel A
AU  - de la Cruz, Luis
AU  - Cerezuela, Pablo
AU  - Arance, Ana
AU  - Muñoz-Couselo, Eva
AU  - Espinosa, Enrique
AU  - Puertolas, Teresa
AU  - Diaz Beveridge, Roberto
AU  - Ochenduszko, Sebastian
AU  - Villanueva, Maria-Jose
AU  - Basterretxea, Laura
AU  - Bellido, Lorena
AU  - Rodriguez, Delvys
AU  - Campos, Begoña
AU  - Montagut, Clara
AU  - Drozdowskyj, Ana
AU  - Molina, Miguel A
AU  - Lopez-Martin, Jose Antonio
AU  - Berrocal, Alfonso
PY  - 2021
DO  - 10.1038/s41467-021-26572-6
UR  - https://hdl.handle.net/10668/27002
T2  - Nature communications
AB  - Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations. Previous preclinical studies suggested that an intermittent dosing of these...
LA  - en
KW  - Aged
KW  - Antineoplastic Agents
KW  - Azetidines
KW  - Humans
KW  - Imidazoles
KW  - Melanoma
KW  - Mutation
KW  - Oximes
KW  - Piperidines
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins B-raf
KW  - Pyridones
KW  - Pyrimidinones
KW  - Vemurafenib
TI  - Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
TY  - research article
VL  - 12
ER  -